

SUBJECT INDEX

A

Abetalipoproteinemia (ABL),
663-64, 667-86

apolipoprotein

B-containing lipoproteins
and, 667

clinical characteristics,
667-72

lipid metabolism and,
672-74

microsomal triglyceride
transfer protein and,
663-64, 667-86

treatment, 675-78

vitamins E, A deficiency
and, 675-75

Absorption

copper, 291-94

ethanol's effects on, 406
intestinal, 195, 202-13

fasting and malnutrition
and, 205-13

iron, 273-87

adult, 273-75

definitions, 274-75

distinction between iron
retention and, 275

Acetaldehyde, 397

Acyl-CoA-synthetase (ACS)

triacylglycerol synthesis
and, 77, 79-81, 84-88,
92-93

acyl-CoA channeling and,
92-93

exercise and, 90

very-long-chain (VLACS),
80-81

Acyltransferase, 77, 79-81

glycerol-3-phosphate
(GPAT), 81-82

triacylglycerol synthesis

and, 77, 79-82, 85-87,
92-93

Adaptation

calcium and, 1, 7-10

osteoporosis and, 9-10

low-protein diets and, 6-7

Adenylate cyclase, 516-17

Adipocyte

Differentiation

See Adipogenesis

leptin-induced apoptosis
in, 118-19

Adipogenesis

events, 547-49

transcriptional control,
535-50

ADD1/SREBP, 544-46

CCAAT-enhancer-
binding protein, 542

peroxisome proliferator-
activated receptor and,
537-42

Adipose tissue

brown, 339-56, 372-73,
536

mitochondrial

uncoupling protein and,
339-56

thermogenesis, 339-56

hormone-sensitive lipase
and, 365-82

leptin and, 105-19

apoptosis and, 118-19

body fat mass regulation,
105-19

expression and secretion,
107-10

metabolism regulation,
105-19

neuroendocrine effects,
114-15

neuropeptides, 111-12

nutrient flux and, 115-18

receptors, 107

site of action in brain,
110-11

lipolysis in, 365-82

white, 536

Albumin

copper transport and,
293-94

Alcohol

hepatotoxicity, 395-417

cytochrome P4502E1
(CYP2E1) and, 395,
400-1

oxidative stress and,
395, 401, 414

metabolism and interaction
with nutrients, 395-417

alcohol dehydrogenase
(ADH) pathway,
397-400

microsomal ethanol
oxidizing system, 397,
400-1

protein metabolism and,
415-16

three main pathways of,
397

moderate intake, 561

nutrient activation and,
406-9

See also Alcoholics;

Ethanol; Wine

Alcoholics, 395-417

increased vulnerability of,
400-1

methionine deficiency in,
407-8

nutritional status of,
401-6

- nutritional therapy for, 416-17
 phosphatidylcholine activity and, 409
 pyridoxine deficiency in, 406-7
 S-adenosylmethionine depletion and, 407-8
 tolerance to ethanol of metabolic, 400
 nervous system, 400
 Amino acid metabolism diurnal and exercise modulation of, 461-62
 exercise and, 457-64, 471-77
 intermediary, 460
 protein metabolism and, 457-77
 transport, 460
 Amino acids branched-chain, 459
 Anemia iron deficiency, 129-30, 132, 136, 138, 273-74
 cognitive development and, 274
 Anti-obesity drugs brown fat thermogenesis and, 340, 345, 356
 Antioxidants apoptosis and, 485, 493-97
 age-related macular degeneration, 494-95
 atherosclerosis, 496-97
 inhibition of neurodegenerative diseases, 493-94
 Apobec-1, 169, 172-77
 characterization of, 174-77
 genetic and functional, 176-77
 Apolipoprotein B, 169-84
 abetalipoproteinemia and, 663, 672-86
 apobec-1 and, 169, 172-77
 lipoprotein assembly, 169, 178-80
 microsomal triglyceride transfer protein (MTP) and, 169-70, 178-80, 679-86
 mRNA editing, 169-77
 presecretory degradation, 169-70, 180-84
 mechanisms of, 182-84
 Apoptosis age-related macular degeneration, 494-95
 antioxidants and, 495
 atherosclerosis and, 495-47
 antioxidants and, 496-97
 cholesterol and, 497
 zinc and, 497
 carcinogenesis and, 488-93
 butyric acid and, 490-91
 isoflavones and, 485, 491
 monoterpenes and, 491-92
 phase-2 enzyme inducers and, 489-90
 sphingolipids and, 492-93
 definition and functions, 486-88
 diet and, 485-99
 immunity and, 497-98
 zinc and, 498
 leptin and inhibition of, 50
 leptin-induced adipocyte, 118-19
 neurodegenerative diseases and, 493-44
 antioxidants and, 493-44
 Atherosclerosis and, 485, 495-97
 apoptosis and antioxidants and, 496-97
 cholesterol and, 497
 zinc and, 497
 susceptibility, 170
B
 Body fat leptin expression and secretion and, 46-49, 51
 mass regulation leptin and, 105-19
 Body weight regulation of brown fat thermogenesis and, 339-56
 mitochondrial uncoupling protein (UCP1) and, 339-56
 See also Mitochondrial uncoupling protein; Thermogenesis
 Bone, 507, 509, 520-21
 extracellular Ca^{2+} -sensing receptor in distribution and function of, 520-21
 Bone-mineral status maternal, 250-52, 257-59
 lactation and, 257-59
 pregnancy and, 250-52
 Bone turnover, 249, 259-61
 Breast cancer dietary fat and, 221-43
 incidence and mortality statistics, 222-23
 risk estrogen and, 223
 tumor carcinogenesis, 223
 studies analytic studies, 225-26
 animal experiments, 223-24
 assessment tools, 240-41
 case control studies, 233-37
 cohort studies, 233-37
 confounding, 238-39
 correlational studies, 225
 dietary history, 241

- epidemiologic studies, 224-25
 measurement error, 240
 randomized controlled trials, 237
 study design, 238
 variation in exposure, 240
- Breastfeeding**
 intestinal epithelial cells and, 314-16
 iron availability and, 315
 lactoferrin and, 314-16
 See also Human milk
- Brown adipose tissue**
 leptin resistance and, 342-43
 mitochondrial uncoupling protein (UCP1) and, 339-56
 function, 349-51
 homologues, 339-56
 overexpression, 345-48
 structure, 348-49
 nonshivering thermogenesis (NST), 340-56
- Butyrate**, 311-12, 327
 intestinal gene expression and, 311-12
- Butyric acid**
 carcinogenesis and, 490-91
- C**
- Calcitropic hormones**, 249, 253-55
- Calcium**
 dietary guidelines, 1, 7-10
 lactation and, 256-61
 bone-mineral status, 257-59
 breast-milk calcium secretion, 256-57
 calcium requirements, 256
 osteoporosis and, 1, 9-10
 physiological adaptation and, 249
 pregnancy and, 249-56
 bone-mineral status, 250-52
 calcitropic hormones, 249, 253-55
 calcium requirements, 249-50
 recommendations, 263-64
 requirements, 249-50, 256
Calcium homeostasis
 extracellular Ca^{2+} -sensing receptor and, 507-27
 possible central mechanisms of, 522
Calorie restriction
 mucosal mass and, 199
cAMP
 triacylglycerol (TAG) synthesis and, 85, 88-89
Cancer, 22, 382
 breast, 221-43
 colorectal
 exercise and reduction in, 22
 hormone-sensitive lipase and, 382
 isoflavones
 decreased risk and, 491
 See also Breast cancer
Carcinogenesis, 488-93
 apoptosis and, 488-93
 butyric acid and, 490-91
 dietary fat and, 492
 isoflavones and, 485, 491
 monoterpenes and, 491-92
 phase-2 enzyme inducers and, 489-90
 sphingolipids, 492-93
 cytochrome P450 and, 489-90
Cardiovascular disease
 wine's protective effect against, 573-81
- β -Carotene
 adverse reactions of ethanol with, 413-15
- Case-control studies**
 breast cancer and dietary fat, 221, 226-33, 242
- CCAAT enhancer-binding protein (C/EBP)**, 534, 542-44
- C-cells**, 517
- Cell proliferation**
 leptin and, 50
- Ceramide**, 443
- Ceruloplasmin**, 132, 135, 139, 294
- Cholesterol**
 atherosclerosis and, 497
 dietary guidelines, 1, 10-13
 metabolism, 674
- Cholesteryl ester hydrolase**, 365
- Cirrhosis**, 395-417
 nutritional status and, 395-97, 40-46
 See also Alcohol; Hepatotoxicity
- Cohort studies**
 breast cancer and dietary fat, 221, 233-37, 242
- Colorectal cancer**
 exercise and reduction in, 22
- Confounding**, 221, 238-39
- Copper**
 adsorption, 291-94
 chaperones
 copper transport and, 291, 296-97
 nutritional status of alcoholics and, 405
 transport, 291-302
 albumin and, 293-94
 ceruloplasmin and, 294
 copper chaperones and, 291, 296-97
 cytochrome c oxidase

- and, 291, 296-97
 glutathione and, 295-97
 histidine and, 293-94
 membrane transport, 295-97
- Copper metabolism, 291-302
 abnormal
 Menkes gene and, 291, 297-302
 Wilson gene and, 291, 297-302
 albumin and, 293-94
 ceruloplasmin and, 294
 copper chaperones and, 291, 296-97
 copper-transporting
 ATPases and, 291, 297-302
 cytochrome c oxidase and, 291, 296-97
 glutathione and, 295-97
 histidine and, 293-94
 membrane transport and, 295-97
- Coronary heart disease
 exercise and reduction in, 22
- Corticotrophin-releasing
 factor, 54, 112
 leptin-mediated effects, 112
- Crohn's disease
 enteral feeding for, 317, 319, 329-30
- Cytochrome c oxidase, 291, 296-97
- Cytochrome P450
 carcinogenesis and, 489-90
- Cytochrome P4502E1 (CYP2E1)
 conversion of xenobiotics to toxic metabolites by, 400-1
 ethanol-oxidizing activity of, 400
- Cytokines, 311, 316-19
- synthesis in intestinal
 epithelium, 317-19
- ## D
- Deaminase, 153, 156
- Depression
 exercise and, 34
- Diabetes, 365, 381
- Diacylglycerol (DAG), 78, 91, 443
- Dietary assessment
 breast cancer and dietary fat, 221-43
- Dietary fat
 breast cancer and, 221-43
 See also Breast cancer
- Dietary guidelines, 1, 4-17
 calcium, 1, 7-10
 cholesterol, 1, 10-13
 complex carbohydrates, 15
 degenerative diseases and, 14-17
 fats, 1, 10-13
 protein, 1, 4-7
 serum lipids, 1, 10-13
- Dietary Guidelines for Americans*, 1, 13-17
 development of, 13-17
- Diglycerides (DGs), 366
- Dihydroxyacetone-phosphate
 acyltransferase (DHAPAT), 83
- 3,4-Dihydroxy-2-butanone
 4-phosphate, 153
 synthase, 157-58
- Dilinoleoylphosphatidylcholine (DLPC), 395
- Dopamine β -hydroxylase, 343-44
- ## E
- Eicosanoids
 biosynthesis
 modulation by fatty acids, 433, 436
 immuno-modulatory role, 436-37, 439
- prostaglandin and, 436-37, 439
- Electrolytes
 fasting and loss of, 195, 199-205
- Endocytosis, 202-3
- Energy balance
 leptin and, 105-19
- Energy utilization
 leptin and, 52-54
- Enterocyte microvillus
 membrane, 203
- Environmental contaminants, 595-619
 traditional food systems of
 Northern indigenous peoples and, 595-619
 mercury, 605-6
 PCBs, 606-7
 radionuclides, 607
- Enzymes
 triacylglycerol synthesis, 77-94
- Estrogen
 breast cancer risk and, 223
- Ethanol
 atherosclerotic
 cardiovascular disease, 565
 cancer, 566-68
 diabetes, 566
 metabolism, 395-417
 moderate intake, 561
 See also Alcohol
- Exercise, 21-37, 89-90, 457-77
 amino acid metabolism and, 457-64, 471-77
 behavioral determinants of, 21-37
 access, 29-30, 35-36
 body weight, 26
 characteristics of exercise behavior, 30-31
 diet, 27
 exercise history, 25-26

- health risk profiles, 26-27
injury, 31
motivation, 21, 24, 33-34
self-efficacy, 21, 25, 34
social support, 28, 36-37
stress, 27-28
time, 29, 35-36
benefits, 22
connective tissue
 metabolism and, 469
depression and, 34
environmental strategies to
 support, 36-37
nutritional requirements,
 475-77
protein metabolism,
 457-77
 response to exercise
 training, 470-71
smoking and, 27, 33
triacylglycerol synthesis
 and, 89-90
Extracellular Ca^{2+} -sensing
 receptor, 507-27
 in bone and cartilage,
 520-21
 calcium homeostasis and,
 507-27
 cloning of, 513-14
 homology, 515-16
 in intestine, 521
 in kidney, 518-20
 Mg^{2+} , water, salt
 metabolism and,
 523-27
 in parathyroid gland, 517
 in placenta, 521-22
 signal transduction
 pathways, 516-17
 structure, 515
- F**
Fasting
 intestinal transport and,
 195-214
- ion transport, 199-205,
 213-14
 mechanisms underlying
 changes in, 203-7
 nutrient transport,
 205-14
- Fat**
 Adipogenesis
 See Adipogenesis
 dietary guidelines, 1,
 10-13, 15
 See also Adipose tissue;
 Brown adipose tissue
 Fatty acid mobilization,
 365-82
 hormone-sensitive lipase
 and, 365-82
 Fatty acids
 acyl-CoA-synthase and, 80
 dietary guidelines, 1,
 10-13
 free, 433-44
 metabolic conversion, 433
 modulation of immune
 response by, 431-51
 monosaturated, 12-13
 peroxisome
 proliferator-activated
 receptors and, 431,
 445-51
 activation of, 445-47
 polyunsaturated (PUFAs),
 433, 436, 444, 450-51
 Ferriredutases, 129, 136-38
 Ferritin, 627, 631-65
 Ferroxidases, 129, 132, 135,
 139
 Folic acid
 nutritional status of
 alcoholics, 403-4, 406
 Flavanoids, 568-72
 Flavinogenic organisms
 See Riboflavin
 Food contaminants, 595-619
 mercury and other heavy
 metals, 605-6
 Northern indigenous
 peoples traditional food
 systems, 595-619
 PCBs, 606-7
 radionuclides, 607
 Food intake
 leptin and, 105-19
- G**
Gene expression
 nutritional regulation of
 intestinal
 See Intestinal gene
 expression
 Glutathione
 copper transport and,
 295-97
 Glycagon
 triacylglycerol synthesis
 and, 85, 88
 Glycerol-3-phosphate
 acyltransferase (GPAT),
 81-82
 triacylglycerol synthesis
 and, 81-82
 Gonadotropin secretion
 leptin and, 114
 Growth factors
 intestinal gene expression
 and, 319
 leptin and, 50-54
 Growth hormone
 leptin and, 114
 Growth hormone releasing
 hormone
 leptin and, 51-52
 Guanosine triphosphate
 (GTP), 153-56
 GTP cyclohydrolase II, 156
 GTP
 See Guanosine
 triphosphate
- H**
Health behavior
 transtheoretical model, 25
Heavy metals, 605-6
Hepatotoxicity

- alcohol, 395-417
 cytochrome P4502E1
 and, 395, 400-1
 metabolism of proteins
 and, 415-16
 oxidative stress and,
 395, 401, 414
 toxic interaction with
 nutrients, 409-15
 See also Alcohol;
 Alcoholics
- Hephaestín, 139
- Hereditary hemochromatosis,
 130, 134
- Histidine
 copper transport and,
 293-94
- Hormone-sensitive lipase,
 365-82
 in adipose tissue, 365-82
 in brown adipose tissue,
 372-73
 cancer and, 382
 diabetes and, 381
 familial combined
 hyperlipidemia and,
 380-81
 lipolysis and, 365-82
 metabolic syndrome and,
 381
 in muscle, 371-72
 in pancreatic β -cells,
 373-74
 properties, 366-67
 reversible protein
 phosphorylation, 375-76
 structure, 367-71
- Human milk, 699-719
 oligosaccharides and,
 699-719
 brain development and,
 717-18
 concentrations of, 703-6
 galactose studies,
 711-17
 immunomodulatory
 effects of, 709-11
- infants' renal excretion
 of, 711
 nonspecific defense
 mechanisms of, 707-11
 prebiotic effects of,
 706-7
 structural diversity of,
 700-3
- Hyperlipidemia
 familial combined, 380-81
- Hypertension
 exercise and reduction in,
 22
- Hypothalamic-pituitary-
 adrenal (HPA) axis,
 54-58, 114-15
 inflammatory response
 and, 56-58
 leptin and, 54-58, 114-15
- Hypothalamic-pituitary
 gonadal axis, 59-60
 leptin and, 59-60
- Hypothalamic-pituitary-
 thyroid (HPT) axis,
 58-59
 leptin and, 58-59
- I**
- Immune response
 fatty acids and, 431-51
 peroxisome
 proliferator-activated
 receptors and, 431,
 445-51
- Immunity, 485, 497-98
 apoptosis and, 497-98
 zinc and, 498
- Indigenous peoples
 contamination of
 traditional food systems,
 595-619
 dilemmas posed by,
 615-19
 mercury and other heavy
 metals, 605-6
 PCBs, 606-7
 radionuclides, 607
- Infant metabolism, 699-719
 oligosaccharides in human
 milk and, 699-719
 brain development and,
 717-18
 concentrations of, 703-6
 galactose studies,
 711-17
 immunomodulatory
 effects of, 709-11
 nonspecific defense
 mechanisms of, 707-11
 prebiotic effects of,
 706-7
 renal excretion of, 711
 structural diversity of,
 700-3
- Inflammatory response
 leptin and, 56-58
- Insulin
 intestinal gene expression
 and, 311-12, 327-29
 leptin and expression of,
 48-49
 leptin and insulin
 sensitivity, 45-50
 leptin and secretion of,
 47-49
 lipolysis in adipose tissue
 and, 374
 triacylglycerol synthesis
 and, 85
- Intestinal gene expression,
 311-30
 cytokines and, 311, 316-19
 growth factors and, 319-20
 lactoferrin and, 314-16
 luminal environment and
 butyrate, 311-12
 carbohydrates, 321-22
 fat, 324-25
 insulin, 311-12, 327-29
 proteins, 323
 vitamins and minerals,
 325-26
 major histocompatibility
 complex, 319

- mucosal immune system and, 311, 316-17
- Intestinal transport, 195-214
- fasting and malnutrition and, 195-214
 - ion transport, 199-205
 - nutrient transport, 205-13
 - mechanisms underlying changes in, 203-7
- Intestine, 311, 311-30, 507, 509, 521
- epithelium, 311
 - extracellular Ca^{2+} -sensing receptor
 - distribution and function of, 521
 - mucosal immune system, 311, 316-17
- See also Intestinal gene expression; Intestinal transport
- Iron
- absorption and regulation, 129, 131-32, 273
 - deficiency, 129-30, 132, 136, 138, 273-74
 - ^{59}Fe whole-body counting, 273, 275-77, 282
 - homeostasis, 129
 - metabolism, 627-65
 - cellular iron use, 631-32
 - iron export, 632-33
 - iron regulatory proteins and, 627-65
 - iron transport and uptake, 129-40, 630-31
 - transcriptional control, 633-35
 - nutritional status of
 - alcoholics, 405
 - overload, 129-30
 - retention by infants, 273-87
 - age and, 284
 - iron dose/concentration of feeding, 285
 - iron nutritional status and, 284-85
 - studies, 277-83
 - term versus preterm infants, 285
 - type of feeding and, 284
 - utilization, 286
 - transport, 129-40
 - membrane systems, 136-39
 - molecular mechanisms, 139-40
 - nontransferrin-bound iron uptake, 134-36
 - transferrin-mediated iron delivery, 132-36
- Iron regulatory proteins, 131, 140, 627-65
- diversity of function, 643
 - hypoxia and, 645-46
 - nitric oxide and, 643-44
 - oxidative stress and, 644-45
 - phosphorylation and, 646-48
 - regulation of ferritin and transferrin receptor synthesis, 636-38
- Iron-responsive elements, 133, 139
- Isoflavones, 485, 491
- decreased cancer risk and, 491
- K**
- Kidney
- extracellular Ca^{2+} -sensing receptor in
 - distribution and function of, 518-20
 - Mg^{2+} , water, and salt metabolism and, 523-27
- L**
- Lactobacillus casei*, 3
- Lactoferrin, 135, 314-15
- breast milk and, 314-16
- Leptin, 45-62
- apoptosis inhibition and, 50
 - body fat mass regulation and, 105-19
 - brown fat and, 342-43, 346
 - expression and secretion, 107-10
 - as growth factor, 50-54
 - insulin
 - expression and, 48-49
 - secretion and, 47-49
 - sensitivity and, 45-50
 - leptin-induced apoptosis in adipocytes, 118-19
 - lipid metabolism and, 116-17
 - metabolism regulation and, 105-19
 - neuroendocrine effects, 114-15
 - neuropeptides and, 111-13
 - corticotrophin-releasing factor, 112
 - melanocortin system, 112-13
 - neuropeptide Y, 111-12
 - nutrient flux and, 115-18
 - reproduction and, 59-61
 - satiety and, 45-46
 - sites of action, 110-11
 - stress and, 54-59
 - sympathetic nervous system and, 113
 - triacylglycerol synthesis and, 77, 87-88
- Lipid metabolism
- leptin and, 116-17
- Lipid peroxidation
- iron overload and, 130
- Lipolysis, 365-82
- cAMP-mediated activation of, 376-77
 - hormone-sensitive lipase and, 365-82
 - molecular mechanisms in, 374-77
- Lipoprotein lipase, 366

- Lipoproteins**
 apolipoprotein B (ApoB)
 and, 169–84
 assembly of
 kinetics of, 178
 low-density, 170–84
 apobec-1 and, 172–77
 microsomal triglyceride
 transfer protein (MTP)
 and, 169–70
 plasma
 abetalipoproteinemia
 and, 663, 672–86
 microsomal transfer
 protein and, 679–86
- Liver disease**
 alcoholic
 See Alcohol; Alcoholics;
 Hepatotoxicity
- Lumazine**, 153, 158–59
 synthase, 158–59
- Lysophosphatidic acid**
 acyltransferase
 (LPAAT), 81–82
- M**
- Magnesium**
 nutritional status of
 alcoholics and, 405
- Major histocompatibility
 complex**, 319
- Malnutrition**
 alcohol toxicity and,
 395–417
 metabolism of proteins
 and, 415–16
 nutritional status of
 alcoholics and, 401–6
 toxic interaction of
 alcohol with nutrients,
 409–15
 intestinal transport and
 ion transport and,
 199–205, 213–14
 nutrient transport,
 205–14
- Melanocortin system**
 leptin-mediated effects,
 111–12
- Menkes gene**
 abnormal copper
 metabolism and, 291,
 297–302
- Mercury**, 605–6
- Metabolism regulation**
 leptin and, 105–19
 carbohydrate
 metabolism, 117–18
 energy metabolism, 116
 lipid metabolism,
 116–17
- Metal homeostasis**
 iron regulatory proteins
 See Iron regulatory
 proteins
- Methionine**
 deficiency in alcoholics,
 407–8
- Microsomal triglyceride
 protein (MTP)**, 663–86
 abetalipoproteinemia and,
 663–64, 667–86
 heterodimeric structure,
 664–65
 hyperlipidemia treatment
 and, 686
 lipid transfer activity, 666
 plasma lipoprotein
 assembly and, 679–86
 tertiary structure model,
 666
- Microsomal triglyceride
 transfer protein**, 169–70,
 178–83
- Mitochondrial uncoupling
 protein (UCP1)**, 339–56
 brown fat thermogenesis
 and, 339–56
 genetic manipulation of,
 342–46, 355–56
 fatty acids and, 351–52
 function, 349–51
 homologues, 339–56
 expression, 355–56
- function, 354–55
 structure, 352–54
 overexpression, 345–48
 structure, 348–49
- Mitogen-activated protein
 kinase**, 516
- Monoacylglycerol
 acyltransferase (MGAT)**,
 83–84
- Monoglyceride lipase**, 366
- Monoterpenes**
 tumorigenesis inhibition
 and, 491–92
- Mucosa**, 275, 195–214
 iron absorption and, 275
 mucosal mass
 calorie restriction and,
 199
 fasting and malnutrition
 and, 198–99
 oxidative stress and, 205
- Mucosal immune system**
 intestinal gene expression
 and
 nutritional regulation of,
 311, 316–17
- Myristic acid**, 12
- N**
- Neurogenerative diseases**
 apoptosis and
 antioxidants and,
 493–94
- Neuropeptide Y**
 leptin-mediated effects
 and, 111–12
- Nutrient absorption**
 fasting and malnutrition
 and, 195, 202–13
- Nutrient flux**
 leptin and, 105, 115–18
 carbohydrate
 metabolism, 117–18
 energy metabolism,
 116–17
 lipid metabolism,
 116–17

O

- Obesity
 - anti-obesity drugs, 340, 345, 356
 - brown fat thermogenesis and, 339-56
 - genetic manipulation of, 342-46, 355-56
 - mitochondrial uncoupling protein and, 339-56
 - exercise and reduction in, 22
 - hormone-sensitive lipase and, 365, 382, 379-80, 382
 - leptin and, 105-19
 - triacylglycerol synthesis and, 77, 90-91
 - Oligosaccharides
 - human milk and, 699-719
 - brain development and, 717-18
 - concentrations of, 703-6
 - galactose studies, 711-17
 - immunomodulatory effects of, 709-11
 - infants' renal excretion of, 711
 - nonspecific defense mechanisms of, 707-11
 - prebiotic effects of, 706-7
 - structural diversity of, 700-3
 - Osteoporosis, 1, 9-10
 - calcium intake and, 9-10
 - exercise and reduction in, 22
 - Western-style diet and, 10
 - Oxidative stress
 - alcohol metabolism and, 395, 401, 414
 - apoptosis and, 485, 493-97
 - age-related diseases and, 485
 - atherosclerosis and, 495-97
 - neurodegenerative diseases and, 493-94
 - fasting and, 205
 - iron regulatory protein and, 644-45
- P**
- Parathyroid
 - extracellular Ca^{2+} -sensing receptor and, 507, 517
 - distribution and function of, 517
 - hormone secretion, 507, 513-14
 - PCBs in food, 606-7
 - Permeability
 - intestinal, 195, 202-5
 - fasting and malnutrition and, 195, 202-5
 - Perilipin, 365
 - Peroxisome
 - proliferator-activated receptor (PPAR), 77, 86-87, 347, 431, 445-49, 535, 537-42
 - adipocyte differentiation and, 535, 537-42
 - fatty acid activation of, 445-47
 - immune and inflammatory responses and, 431, 447-49
 - triacylglycerol synthesis and, 77, 86-87
 - Phase-2 enzyme inducers
 - apoptosis and, 485, 489-90
 - Phosphatidate
 - phosphohydrolase (PPH-1), 83
 - Phospholipases, 516
 - Physical activity
 - See Exercise
 - Pituitary-derived growth hormone
 - leptin and, 51-52
 - Placenta
 - extracellular Ca^{2+} -sensing receptor in, 521-22
 - distribution and function of, 521-22
 - Polyenylphosphatidylcholine (PPC), 395, 409
 - liver disease and, 395, 409
 - Polyunsaturated fatty acid (PUFA), 86
 - PPAR
 - See Peroxisome proliferator-oriented receptor
 - Pregnancy-induced hypertension, 249, 255-56
 - Prostaglandin receptors, 431, 439-40
 - Prostaglandins
 - immunomodulatory roles of dietary fatty acids, 431, 436-37, 439-51
 - receptor-mediated signaling pathways and, 439-40
 - Proteasomes, 169-70, 180-83
 - Protein, 1, 4-7, 415-16, 464-77
 - adaptation to low-protein diets, 6-7
 - breakdown, 468-77
 - dietary requirements, 4-7
 - growth and, 6-7
 - metabolism
 - effects of ethanol on, 415-16
 - nitrogen balance and, 4
 - synthesis, 464-77
 - turnover, 465-77
 - Protein disulfide isomerase, 663
 - Protein kinase A, 365
 - Pyridoxine
 - deficiency in alcohols, 406-7

- R**
- Radionuclides, 607
 - Receptor-mediated signaling pathways
 - modulation by dietary fatty acids, 431, 439–51
 - prostaglandin E receptors and, 439–40
 - Reductase, 153, 156
 - Reproduction
 - leptin and, 45, 59–61
 - Riboflavin
 - nutritional status of alcoholics, 404
 - Ribulose 5-phosphate, 153
 - Riboflavin (vitamin B₂)
 - biosynthesis, 153–61
 - genetics and regulation, 161
 - deaminase and, 153, 156
 - reductase and, 153, 156
 - 3,4-dihydroxy-2-butanone-4-phosphate synthesis and, 157–58
 - guanosine triphosphate and, 153–54, 156
 - lumazine and, 153, 158–59
 - pathway, 154–56
 - synthase, 160–61
- S**
- S-adenosylmethionine (SAME), 395, 407–8
 - deficiency in alcoholics, 407–8
 - Satiety
 - leptin and, 45–46
 - Secretion
 - intestinal, 195, 201–2
 - fasting and malnutrition and, 201–2
 - Sedentary behavior, 21–37
 - behavioral determinants of exercise and, 21–37
 - See also Exercise
 - Selenium
 - nutritional status of alcoholics, 404
 - Sexual maturation
 - leptin and, 60–61
 - Skeletal muscle
 - amino acid metabolism and, 458–64
 - diurnal and exercise modulation of, 461–62
 - intermediary, 460
 - transport, 460
 - composition and function, 459–60
 - fuel metabolism in, 462–64
 - protein metabolism and, 458–59, 464–59
 - Smoking
 - exercise and, 27, 33
 - Sphingolipids
 - protective effect against cancer, 492–93
 - SREBP, 77, 85–86
 - transcriptional control of adipogenesis and, 535, 544–46
 - transcriptional regulation of triacylglycerol synthesis by, 85–86
 - Stable isotopes
 - iron retention in infants and, 273, 275–87
 - Stress
 - leptin and, 45, 54–59

T

 - Thermogenesis, 339–56
 - brown fat–derived nonshivering (NST), 340–56
 - genetic manipulation of, 342–46, 355–56
 - mitochondrial uncoupling protein homologues and, 339–56
 - Thiamine
 - deficiency in alcoholics, 406–7
 - Trace minerals
 - nutritional status of alcoholics and, 406
 - Transferrin
 - iron transport and, 129–40
 - receptors, 129, 627, 630–65
 - molecular control of iron metabolism and, 627, 630–65
 - Translocation, 169, 182–84
 - Transtheoretical model, 25, 34–35
 - Triacylglycerol (TAG)
 - synthesis, 77–94
 - enzymes of
 - acyl-CoA synthetase (ACS), 79–81
 - diacylglycerol acyltransferase, 84
 - dihydroxyacetone-phosphate acyltransferase (DHAPAT), 83
 - glycerol-3-phosphate acyl transferase (GPAT), 81–82
 - lysophosphatidic acid acyltransferase (LPAT), 81–82
 - monoacylglycerol acyltransferase (MGAT), 83–84
 - nutritional control of, 85–89
 - phosphatidate phosphohydrolase (PPH-1), 83
 - physiological control of, 89–91
 - obesity and, 90–91
 - transcriptional regulation, 85–90
 - exercise and, 89–90
 - hormones and, 85, 88–89
 - leptin and, 87–88

- peroxisome
 proliferator-activated
 receptor (PPAR), 77,
 86-87
 SREBP and, 85-86
 Triglycerides (TG), 365-66
 hydrolysis of, 366
 Tumor carcinogenesis
 fat and, 223
- U**
- Ubiquitin, 169, 170, 180-83
- V**
- Vitamin A
 adverse reaction of ethanol
 with, 409-13
 deficiency, 674-75
 Vitamin B₂ (riboflavin)
 biosynthesis, 153-61
 genetics and regulation,
 161
 deaminase and, 153, 156
 reductase and, 153, 156
 3,4-dihydroxy-2-butanone-
 4-phosphate synthesis
 and, 157-58
- guanosine triphosphate
 and, 153-54, 156
 lumazine and, 153, 158-59
 pathway, 154-56
 synthase, 160-61
 Vitamin B₁₂
 nutritional status of
 alcoholics, 404
 Vitamin C
 nutritional status of
 alcoholics, 402-3
 Vitamin D
 nutritional status of
 alcoholics, 403
 Vitamin E
 deficiency, 672, 674-75
 nutritional status of
 alcoholics, 404
 Vitamin K
 nutritional status of
 alcoholics, 403
- W**
- Wernicke-Korakoff
 syndrome, 406
 Wilson gene, 291,
 297-302
- abnormal copper
 metabolism and, 297-302
 Wine
 cancer and, 566-68
 cardiovascular disease and,
 573-81
 flavonoids in, 568-72
 health benefits of, 561-82
 lipoprotein
 biology, 573-75
 oxidation of low-density,
 576-77
 nonalcoholic components,
 568-70
 oxidative susceptibility,
 577-78
 vascular-wall biology,
 578-81
- Z**
- Zinc, 405, 485, 497, 498
 apoptosis and
 atherosclerosis and,
 497
 immunity and, 498
 nutritional status of
 alcoholics, 405

